Last updated: June 4, 2026
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE Suppliers: API and Finished-Dose Sourcing Map
Demand is concentrated around a single branded product: Nuedexta (dextromethorphan HBr/quinidine sulfate). Supplier options depend on whether you need API (active pharmaceutical ingredient) or finished-dose. Without a verified regulatory-grade sourcing list and current Orange Book/NDC linkage, a complete, decision-ready supplier roster cannot be produced.
Who supplies dextromethorphan hydrobromide (API) and quinidine sulfate (API) for Nuedexta?
Direct API sourcing is typically structured through large API manufacturers and distributor networks that support NDA commercial supply, plus secondary suppliers for development-scale manufacturing. For this specific combination, supplier visibility is constrained because the market is dominated by one FDA-approved combination product and commercial procurement practices are not fully disclosed publicly.
What dextromethorphan hydrobromide manufacturers supply commercially?
No complete and citable list of current, FDA-relevant API manufacturers can be produced from the information provided.
What quinidine sulfate manufacturers supply commercially?
No complete and citable list of current, FDA-relevant API manufacturers can be produced from the information provided.
What finished-dose manufacturers supply dextromethorphan HBr and quinidine sulfate tablets/capsules (NDC) in the US?
The finished-dose supply chain is tied to the marketed product’s NDA and label. A decision-grade supplier list requires NDC-level mapping to the actual manufacturing sites and labeler/marketing authorizations.
Which sites manufacture the Nuedexta combination product?
A specific site-and-supplier table cannot be generated without verified NDC/labeler/manufacturer records.
Are there contract manufacturing (CMO) routes for this combination?
Public CMO attribution for this exact combination at commercial scale is not determinable from the information provided.
How do procurement routes differ for API versus finished-dose dextromethorphan HBr/quinidine sulfate?
API route
Typical procurement paths include:
- API supply from qualified API manufacturers
- use of approved intermediates chains
- distributor-based sourcing only after qualification
Finished-dose route
Typical procurement paths include:
- acquisition of finished product from the NDA holder’s commercial supply chain
- contract supply from authorized manufacturers for the labeler/NDC
A definitive “who supplies whom” map requires current regulatory product listings and site records.
What regulatory status constrains supplier qualification for dextromethorphan/quinidine?
What matters for supplier acceptance
For US drug supply, supplier qualification commonly hinges on:
- DMF status (if applicable)
- current GMP inspection history
- batch release testing documentation
- impurity profile consistency
- stability and formulation compatibility
A citable regulatory constraint map cannot be completed without the underlying public regulatory records for each supplier and site.
What documentation is required to qualify a new dextromethorphan HBr/quinidine sulfate API supplier?
Decision-ready qualification typically uses:
- CoA and CoC
- DMF or ASMF cross-reference (where relevant)
- impurity and residual solvent specs
- stability data
- manufacturing process description
Without the supplier set and their regulatory identifiers, this cannot be translated into an actionable sourcing plan.
What generic entry risks exist for dextromethorphan HBr/quinidine sulfate suppliers?
Supplier risk profiles depend on whether the combination is protected from generic competition and whether formulations are tightly constrained. Supplier qualification and continuity planning require:
- patent and exclusivity mapping
- regulatory pathway risks (e.g., ANDA feasibility)
- potential bioequivalence and formulation restrictions
No patent/exclusivity and regulatory entry analysis can be delivered from the information provided.
Key Takeaways
No decision-ready supplier list for dextromethorphan hydrobromide and quinidine sulfate can be produced from the information provided. A complete answer requires verifiable, citable regulatory and product listing evidence that maps suppliers to:
- API manufacturers and sites
- finished-dose manufacturers and NDC labelers
- current US market supply reality
FAQs
- Which companies currently hold the commercial supply chain for Nuedexta dextromethorphan/quinidine in the US?
- How can an API supplier demonstrate GMP compliance for dextromethorphan HBr and quinidine sulfate?
- What DMF/ASMF markers typically govern API supplier qualification for fixed-dose combinations?
- What batch release and impurity controls are critical for quinidine sulfate API sourcing?
- How does finished-dose NDC mapping determine the true manufacturing suppliers for dextromethorphan/quinidine?
References
No sources were provided in the prompt, and no citable regulatory or listing records were included.
